Olsalazine SodiumCAS# 6054-98-4 |
- Cefditoren Pivoxil
Catalog No.:BCC4898
CAS No.:117467-28-4
- Balofloxacin
Catalog No.:BCC4892
CAS No.:127294-70-6
- Pefloxacin Mesylate Dihydrate
Catalog No.:BCC5089
CAS No.:149676-40-4
- Tinidazole
Catalog No.:BCC4866
CAS No.:19387-91-8
- Toltrazuril
Catalog No.:BCC4870
CAS No.:69004-03-1
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 6054-98-4 | SDF | Download SDF |
| PubChem ID | 135413505 | Appearance | Powder |
| Formula | C14H8N2Na2O6 | M.Wt | 346.2 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | H2O : 50 mg/mL (144.43 mM; Need ultrasonic) DMSO : 20 mg/mL (57.77 mM; Need ultrasonic) | ||
| Chemical Name | disodium;2-carboxy-4-[(3-carboxy-4-oxidophenyl)diazenyl]phenolate | ||
| SMILES | C1=CC(=C(C=C1N=NC2=CC(=C(C=C2)[O-])C(=O)O)C(=O)O)[O-].[Na+].[Na+] | ||
| Standard InChIKey | ZJEFYLVGGFISGT-UHFFFAOYSA-L | ||
| Standard InChI | InChI=1S/C14H10N2O6.2Na/c17-11-3-1-7(5-9(11)13(19)20)15-16-8-2-4-12(18)10(6-8)14(21)22;;/h1-6,17-18H,(H,19,20)(H,21,22);;/q;2*+1/p-2 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Olsalazine is an anti-inflammatory drug used in the treatment of Inflammatory Bowel Disease and Ulcerative Colitis.
Target: Antibacterial
Olsalazine is a derivative of salicylic acid. Inactive by itself (it is a prodrug), it is converted by the bacteria in the colon to mesalamine. Olsalazine is potent inhibitors of human intestinal macrophages chemotaxis to LTB4 with IC50 of 0.39 mM. Olsalazine (0.4 mM) inhibits the superoxide radical production generated by phorbol myristate acetate (PMA)-activated neutrophils or by xanthine-xanthine oxidase reaction by reduction of 31% and 73%, respectively. Olsalazine inhibits tumor growth in a rodent model of colorectal cancer. In 1,2-dimethylhydrazine-treated rats, Olsalazine (25 mg/kg/day) decreases number and volume of tumors by 58.17% and 62.67%, respectively. Administration of Olsalazine induces a 1.7-fold times increase in the number of apoptotic cells, companied with a reduction of 42.4% in cell proliferation rate. References: | |||||
Olsalazine Sodium Dilution Calculator
Olsalazine Sodium Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.8885 mL | 14.4425 mL | 28.885 mL | 57.7701 mL | 72.2126 mL |
| 5 mM | 0.5777 mL | 2.8885 mL | 5.777 mL | 11.554 mL | 14.4425 mL |
| 10 mM | 0.2889 mL | 1.4443 mL | 2.8885 mL | 5.777 mL | 7.2213 mL |
| 50 mM | 0.0578 mL | 0.2889 mL | 0.5777 mL | 1.1554 mL | 1.4443 mL |
| 100 mM | 0.0289 mL | 0.1444 mL | 0.2889 mL | 0.5777 mL | 0.7221 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Olsalazine Sodium is a mesalamine dimer.
- Braylin
Catalog No.:BCN4118
CAS No.:6054-10-0
- Methyloleoside
Catalog No.:BCN8079
CAS No.:60539-23-3
- H-D-Thr-OMe.HCl
Catalog No.:BCC2675
CAS No.:60538-15-0
- Zimelidine dihydrochloride
Catalog No.:BCC7173
CAS No.:60525-15-7
- 5,6-Dihydropyridin-2(1H)-one
Catalog No.:BCN4013
CAS No.:6052-73-9
- Serpentinic acid
Catalog No.:BCN4616
CAS No.:605-14-1
- Pifithrin-β
Catalog No.:BCC5503
CAS No.:60477-34-1
- Cytisine Hydrochloride
Catalog No.:BCN8133
CAS No.:6047-01-4
- Cauloside F
Catalog No.:BCN3848
CAS No.:60451-47-0
- Neopetasitenine
Catalog No.:BCN2114
CAS No.:60409-51-0
- Cucurbitacin A
Catalog No.:BCN2468
CAS No.:6040-19-3
- Tombozine
Catalog No.:BCN4117
CAS No.:604-99-9
- Gomisin D
Catalog No.:BCN2268
CAS No.:60546-10-3
- 1-Acetyltagitinin A
Catalog No.:BCN4119
CAS No.:60547-63-9
- P1075
Catalog No.:BCC7027
CAS No.:60559-98-0
- DCEBIO
Catalog No.:BCC7060
CAS No.:60563-36-2
- Tirandamycin B
Catalog No.:BCN1862
CAS No.:60587-14-6
- Pamabrom
Catalog No.:BCC1835
CAS No.:606-04-2
- 2,4'-Dihydroxybenzophenone
Catalog No.:BCN3358
CAS No.:606-12-2
- Toyocamycin
Catalog No.:BCC8047
CAS No.:606-58-6
- Cinnabarinic acid
Catalog No.:BCC7865
CAS No.:606-59-7
- Homopterocarpin
Catalog No.:BCN4615
CAS No.:606-91-7
- MK-0773
Catalog No.:BCC1754
CAS No.:606101-58-0
- Momor-cerebroside I
Catalog No.:BCN4120
CAS No.:606125-07-9
Experimental colitis induced by dextran sulphate sodium in mice: beneficial effects of sulphasalazine and olsalazine.[Pubmed:9768537]
Aliment Pharmacol Ther. 1998 Sep;12(9):925-34.
BACKGROUND: Animal models of inflammatory bowel disease are artificial and more or less representative of human disease. However, the dextran sulphate sodium (DSS) induced intestinal inflammation model has recently been shown to fulfil some pathological criteria for an adequate experimental model. AIM: To determine whether this form of experimental intestinal inflammation responds to established therapy used for human inflammatory bowel disease. METHODS: DSS was used to induce intestinal inflammation in conventional Balb/c mice and athymic nu/nu CD-1(BR) mice, and the well-documented 5-aminosalicylic acid (5-ASA) based anticolitis drugs sulphasalazine (SASP) and olsalazine (OLZ) were used to study therapeutic effects. Parameters which have been shown to reflect DSS-induced intestinal inflammation (body weight, colon length, spleen weight, diarrhoea, and rectal bleeding) were measured in the Balb/c mice. RESULTS: Significant amelioration was seen on these parameters after different treatment protocols. Survival in nu/nu CD-1 mice was studied, and after 16 days a death rate of 50% was noted in the DSS group. SASP (100 mg/kg/day) and OLZ (50 mg/kg/day) significantly prolonged the survival to 29 and 38 days, respectively. SASP and OLZ showed a dose-dependent effect in the range between 10 and 100 mg/kg/day, doses closely corresponding to those used in humans. CONCLUSIONS: SASP and OLZ are able to ameliorate the DSS-induced intestinal inflammation. The dose-response patterns suggested that the active therapeutic moiety for the two drugs appears to be mainly the liberated 5-ASA molecule.
Effect of olsalazine on sodium-dependent bile acid transport in rat ileum.[Pubmed:7729283]
Dig Dis Sci. 1995 May;40(5):943-8.
Olsalazine (OLZ), a relatively new form of 5-aminosalicylic acid (5-ASA), is being used for the treatment of colitis. A major side effect of olsalazine is diarrhea, reported in 12-25% of patients. One suggested mechanism for this side effect is enhanced ileal water and electrolyte secretion. We propose that OLZ may also inhibit ileal bile acid (BA) transport, resulting in choleretic diarrhea. This would result in excess BAs reaching the colon, with consequent BA-induced secretory diarrhea. Therefore, we studied the effect of OLZ on rat ileal absorption of taurocholate. BA uptake was determined in rat ileal segments, everted sacs, brush border membrane vesicles (BBMV), and Xenopus laevis oocytes. Segments and everted sacs were treated with 5 mM OLZ for 30 min prior to and throughout 10-min taurocholate (Tc) uptake. Terminal ileal BBMV were used to study the effect of OLZ on sodium-dependent bile acid uptake independent of cellular metabolism. Direct effects on the bile acid carrier were examined using Xenopus laevis oocytes expressing the cloned apical rat ileal BA transporter. In ileal segments 5 mM OLZ inhibited 10-min Tc uptake by 69.4 +/- 8.8% (P < 0.01) (N = 10 animals). Increasing concentrations of OLZ resulted in a dose-dependent inhibition of Tc uptake. Ten-minute Tc uptake with 0.5, 1.0, 2.0, 2.5, and 5 mM OLZ was inhibited by 13.5, 39.6, 49.7, and 70.5%, respectively. In BBMV, OLZ inhibited 45-sec Tc uptake in a dose-dependent manner but did not effect Na-dependent L-alanine uptake.(ABSTRACT TRUNCATED AT 250 WORDS)
Determination of olsalazine sodium in pharmaceuticals by differential pulse voltammetry.[Pubmed:11534339]
Pharmazie. 2001 Aug;56(8):629-32.
The electrochemical oxidation of Olsalazine Sodium was investigated by cyclic, linear sweep, differential pulse and square wave voltammetry using glassy carbon disc electrode in different buffer systems. Best results were obtained for the determination of olsalazine using the differential pulse voltammetric technique in phosphate buffer at pH 7.0. The electroactive species exhibits a diffusion-controlled voltammetric wave and its differential pulse peak current shows a linear dependence on olsalazine concentration in the range between 2 x 10(-6) M and 2 x 10(-4) M. This relationship has been applied to the determination of olsalazine in commercial capsule dosage forms. The recovery study shows good accuracy and precision for the assay developed. A UV spectrophotometric assay is also reported for comparison.
